PPT-Establishing a model for macular degeneration using CRISPR-Cas9 gene editing and human

A Neiteler 1235 S Borooah 6 BT Selvaraj 235 K Burr 235 B Dhillon 24 JA Ross 1 S Chandran 235 1 Tissue Injury and Repair Group 2 Centre for Clinical Brain Sciences . DeMayo. FJ, Spencer TE. Jennifer Thornton. April 1, 2015. Happy April Fools’ Day!. *I won’t actually cover this paper, but it’s real and you should check it out at. http. ://www.ncbi.nlm.nih.gov/pubmed/25100711. Lauran Maestas. Meghan Raney. Cressie Wright. Three major forms of Juvenile Macular Degeneration. Best’s Disease. Juvenile Retinoschisis. Stargardt Disease. All are rare and cause central vision loss. Introduction to CRISPR. http://. www.addgene.org. /CRISPR/guide/. Wiedenheft. et al. Nature 2012. 3 distinct types of bacterial CRISPR systems identified so far:. Type I, II, III . Type II is the basis for current genome engineering applications. Breakthrough in genome editing.. The most important scientific result . of the year 2015.. “Science“,18 December 2015. I will report first about. Duchenne muscular dystrophy,. because there were serious problems . Nick Turner. Bio 446 Fall 16. Review. siRNA. dsRNA. microRNA. Immunity. Gene Regulation. Enzymatic breakdown of RNA. RNA Interference. RNAi. The use of RNA to inhibit gene expression.. Guiding RISC (RNA Induced Silencing Complex) cleave and degrade specific segments of RNA. The Wonderful World of CRISPR. As told by Professor Peter Shepherd. To do precise genetic engineering we need to be able to find and specifically modify regions of DNA. But the human genome has 3,000,000,000 base pairs so how are we going to find a 20 base pair region in this huge sea of DNA ? . Darryl Benjamin. Real Food Seminars. Montpelier, Vermont. darryl@realfoodseminars.com. 802 585 5855. Updated 08.09.17. What is CRISPR?. CRISPR/Cas9. , is essentially a pair of molecular scissors for . FucU CRIPR/Cas9 KO Plasmid (m): sc-427279 Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe + 00800 4573 8000 49 6221 4503 0 www.scbt.com BACKGR Describe the Gene Editing Technology (CRISPR-Cas9, ZNF, TALENS, Meganucleases) . Describe . the target gene, function of the target gene. and . the desired effect of the target gene in the system (in-vitro/in vivo) . For classroom use with the Out of the Blue CRISPR Kit. explorer.bio-rad.com. Contents. explorer.bio-rad.com. Getting. Started. Getting Started. Instructor Preparation. Student Slides. Introduction. explorer.bio-rad.com. How can we advance CRISPR from a revolutionary research tool to a level of precision and efficiency that will enable us to target ANY genetic disease?. DUAL OMNI™ . TECHNOLOGY PLATFORMS. Novel CRISPR Nuclease Discovery Platform. González. Master in . Advanced. . Genetics. Universitat. . Autònoma. de Barcelona. GENOMICS. Introduction. Francisco J. M. Mojica . CRISPR. 2000. Source. : . Doudna. . y . Charpentier. , 2014. Introduction. successfully applied to directly produce low-copy integrated transgenic lines in C. eleganss10]. High copy integrated arrays are prone to be silenced, yet low-copy transgenes permit relatively stable Page 1 of 10 UnitedHealthcare Commercial Medical Policy Effective 06/01/2022 Proprietary Information of UnitedHealthcare. Copyright 202 2 United HealthCare Services, Inc. UnitedHealthcareCommercial